Court Won't Block Generic Zyprexa In Canada

Law360, New York (March 14, 2008, 12:00 AM EDT) -- The Supreme Court of Canada said on Thursday that it would not hear an appeal by Eli Lilly's Canadian subsidiary of a lower court's decision that allowed Teva Pharmaceutical Industries Inc. subsidiary Novopharm Ltd. to sell a generic version of Lilly's blockbuster antipsychotic Zyprexa.

The court, following its usual practice, gave no reason for denying the appeal. A representative for Eli Lilly could not immediately be reached for comment.

Novopharm began selling Novo-Olanzapine, its version of Zyprexa, last year after winning a patent infringement case brought...
To view the full article, register now.